Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Healthtrust
Merck
AstraZeneca
UBS
Federal Trade Commission
Queensland Health
US Army
Argus Health

Generated: February 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZEPATIER

« Back to Dashboard

Clinical Trials for Zepatier

Trial ID Title Status Sponsor Phase Summary
NCT02743897 Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors Recruiting Merck Sharp & Dohme Corp. Phase 1/Phase 2 This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with Zepatier after the single kidney transplantation.
NCT02743897 Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors Recruiting University of Pennsylvania Phase 1/Phase 2 This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with Zepatier after the single kidney transplantation.
NCT02781649 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Recruiting Merck Sharp & Dohme Corp. Phase 1 In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant.
NCT02781649 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Recruiting Johns Hopkins University Phase 1 In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant.
NCT02786537 Study of Oral Treatments for Hepatitis C Recruiting AbbVie Phase 4 The study will compare the effectiveness of 3 approved HCV treatment regimens to learn whether they work equally well under real-world conditions. Patients receiving HCV therapy in community and academic clinics will be offered the opportunity to consent to be randomly assigned to one of three regimens and then observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management will be assumed by usual care conditions, and patient-reported outcomes will be collected outside clinic in keeping with pragmatic design principles.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Zepatier

Condition Name

Condition Name for Zepatier
Intervention Trials
Hepatitis C 10
Hepatitis C, Chronic 2
Chronic Hepatitis c 2
Renal Failure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zepatier
Intervention Trials
Hepatitis C 19
Hepatitis 16
Hepatitis A 7
Hepatitis C, Chronic 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zepatier

Trials by Country

Trials by Country for Zepatier
Location Trials
United States 31
United Kingdom 2
Taiwan 2
Australia 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zepatier
Location Trials
Massachusetts 4
Pennsylvania 4
Texas 2
Maryland 2
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zepatier

Clinical Trial Phase

Clinical Trial Phase for Zepatier
Clinical Trial Phase Trials
Phase 4 11
Phase 3 2
Phase 2 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zepatier
Clinical Trial Phase Trials
Not yet recruiting 13
Recruiting 6
Suspended 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zepatier

Sponsor Name

Sponsor Name for Zepatier
Sponsor Trials
Merck Sharp & Dohme Corp. 10
University of Pennsylvania 3
Massachusetts General Hospital 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zepatier
Sponsor Trials
Other 21
Industry 11
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Covington
UBS
Federal Trade Commission
Queensland Health
Boehringer Ingelheim
Harvard Business School
US Army
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.